1Berg C, Petersenn S, Lahner H, et al. Cardiovascular risk factors in patients with uncontrolled and long-term acromegaly: comparison with matched data from the general population and the effect of disease control[J].J Clin. Endocrinol Metab, 2010, 95: 3648-3656.
2Holdaway IM, BoUand MJ, Gamble GD. A metanalysis of the effect of lowering serum levels of GH and IGF-1 on mortality in acromegaly. Eur[J]. Endocrinol, 2008, 159: 89-95.
3Colao A, Baldelli R, Marzullo P, et al. Systemic hypertension and impaired glucose tolerance are independently correlated to the severity of the acromegalic cardiomyopathy[J]. J Clin Endocrinol Metab, 2000, 85: 193.
4Giustina A, Barkan A, Casanueva FF, et al. Criteria for cure of acromegaly: a consensus statement[J]. J Clin. Endocrinol Metab, 2000, 85: 526-529.
5Mazziotti G, PorceUi T, Bogazzi F, et al. Effects of highdose octreotide LAR on glucose metabolism in patients with acromegaly inadequately controlled by conventional somatostatin analogtherapy[J]. Eur J Endocrinol, 2011, 164: 341-347.
